Regenxbio (RGNX) Tops Q4 EPS by $1.96

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CRWD
5. CHKP
6. ON
7. HNGE
8. INSP
9. SPY
10. MRVL

Go back to Regenxbio (RGNX) Tops Q4 EPS by $1.96

REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

March 1, 2022 4:05 PM EST

ROCKVILLE, Md., March 1, 2022 /PRNewswire/ --

Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314 Received upfront payment of $370 million and eligible to receive up to $1.38 billion in additional development, regulatory and commercial milestonesContinue to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy Two pivotal trials active for the treatment of wet AMD using subretinal delivery Today announced Cohort 4 enrollment complete in RGX-314 Phase II trial for the treatment of wet AMD... More